Market Closed -
Nasdaq
04:00:00 2024-05-15 pm EDT
5-day change
1st Jan Change
2.21
USD
+0.45%
+3.27%
-9.05%
Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell 2000 Index
June 23, 2023 at 12:00 am EDT
Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell 2000 Index
Athira Pharma, Inc. Appoints Javier San Martin, M.D., as Chief Medical Officer
Apr. 15
CI
Athira Pharma, Inc. Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer's Disease
Apr. 11
CI
Athira Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Feb. 22
CI
Athira Pharma, Inc. Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis
Feb. 08
CI
Athira Pharma, Inc. Provides 2024 Clinical Pipeline Outlook
Jan. 08
CI
Athira Pharma, Inc. Announces Hans Moebius Retires as Chief Medical Officer
Jan. 08
CI
Athira Pharma, Inc. Completes Enrollment of Phase 2/3 Lift-AD Clinical Trial of Fosgonimeton in Mild-To-Moderate Alzheimer's Disease
Jan. 03
CI
Athira Pharma, Inc. Presents Preclinical Data Highlighting Fosgonimeton's Neuroprotective Effects Against Amyloid-B-Induced Pathological Alterations and Neuroinflammation in Models of Alzheimer's Disease
Nov. 15
CI
Athira Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 09
CI
Athira Says Preclinical Results Back Therapeutic Potential of ATH-1105 in ALS; Shares Rise After Hours
23-10-05
MT
JMP Securities Adjusts Athira Pharma Price Target to $19 From $20, Maintains Market Outperform Rating
23-08-11
MT
Athira Pharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-10
CI
Athira Pharma, Inc. Appoints Andrew Gengos as Chief Business Officer
23-08-10
CI
Athira Pharma, Inc. Appoints Andrew Gengos as Chief Financial Officer
23-08-10
CI
Athira Pharma, Inc. Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimerâs Disease
23-07-17
CI
Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell Small Cap Comp Value Index
23-06-23
CI
Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell 3000 Index
23-06-23
CI
Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell Small Cap Completeness Index
23-06-23
CI
Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell 2500 Index
23-06-23
CI
Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell 2000 Index
23-06-23
CI
Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell 3000E Value Index
23-06-23
CI
Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell 3000E Index
23-06-23
CI
Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell 3000 Value Index
23-06-23
CI
Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell 2000 Value Index
23-06-23
CI
Athira Pharma, Inc.(NasdaqGS:ATHA) dropped from Russell 2000 Dynamic Index
23-06-23
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Athira Pharma, Inc. is a late clinical-stage biopharmaceutical company. It focuses on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline consists of both blood brain barrier permeable and peripherally restricted drug candidates for the central nervous system (CNS), peripheral nervous system, and other indications. Its lead candidate, fosgonimeton (ATH-1017), is a subcutaneously administered, small molecule positive modulator of the hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) system for CNS disorders. It is also evaluating other drug candidates for the potential treatment of neuropathic pain, amyotrophic lateral sclerosis, Parkinson's disease, and other neurodegenerative diseases. Its ATH-1020 has completed a Phase I single ascending dose evaluation in healthy volunteers. Its ATH-1105 is a small molecule compound designed to be an orally available, once-daily treatment to enhance the HGF/MET system.
More about the company
Last Close Price
2.21
USD
Average target price
7.417
USD
Spread / Average Target
+235.60%
Consensus
1st Jan change
Capi.
-9.05% 84.7M +29.77% 49.46B +1.00% 42.58B +49.79% 42.49B -5.26% 29.09B +13.68% 26.61B -22.99% 18.64B +8.22% 13.16B +32.41% 12.55B +24.01% 12.1B
Other Biotechnology & Medical Research
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
marketscreener.com**derivatives**en**/dynamic-chart/**Premium**Expert**Access**Annual**Monthly**
-40% Limited Time Offer : Our subscriptions help you unlock hidden opportunities.**#000000**/services/solutions/**#fff826**#ff3000**#ffffff**
BENEFIT NOW **0**linear-gradient(180deg, rgba(42,73,76,1) 0%, rgba(28,30,51,1) 53%);**linear-gradient(180deg, rgba(255, 248, 38,1) 0%, rgba(247, 239,1) 53%);**date_fin_hors_prolongation**49**on all our subscriptions**